Global
Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Barth
Syndrome-Pipeline Review, H2 2018, provides an overview of the Barth
Syndrome (Other Diseases) pipeline landscape.
Barth
syndrome is a rare disorder characterized by dilated cardiomyopathy, skeletal
myopathy, recurrent infections due to neutropenia, and short stature. It is
passed from mother to son through the X chromosome. Symptoms include
cardiomyopathy, skeletal muscle abnormalities, weak muscle tone, increased
levels of organic acids in blood and urine and frequent bacterial infections
such as pneumonia. This occurs exclusively in male. Treatment includes physical
therapy to help with reduced muscle tone and antibiotics for bacterial
infections.
Global
Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Barth
Syndrome-Pipeline Review, H2 2018, provides comprehensive information on the
therapeutics under development for Barth Syndrome (Other Diseases), complete
with analysis by stage of development, drug target, mechanism of action (MoA),
route of administration (RoA) and molecule type. The guide covers the
descriptive pharmacological action of the therapeutics, its complete research
and development history and latest news and press releases.
The
Barth Syndrome (Other Diseases) pipeline guide also reviews of key players
involved in therapeutic development for Barth Syndrome and features dormant and
discontinued projects. The guide covers therapeutics under Development by
Companies /Universities /Institutes, the molecules developed by Companies in
Phase III, Phase II and Preclinical stages are 1, 1 and 2 respectively.
Similarly, the Universities portfolio in Preclinical and Discovery stages
comprises 1 and 1 molecules, respectively.
Barth
Syndrome (Other Diseases) pipeline guide helps in identifying and tracking
emerging players in the market and their portfolios, enhances decision making
capabilities and helps to create effective counter strategies to gain
competitive advantage. The guide is built using data and information sourced
from Global Markets Direct's proprietary databases, company/university
websites, clinical trial registries, conferences, SEC filings, investor
presentations and featured press releases from company/university sites and
industry-specific third party sources. Additionally, various dynamic tracking
processes ensure that the most recent developments are captured on a real time
basis.
The
pipeline guide provides a snapshot of the global therapeutic landscape of Barth
Syndrome (Other Diseases). The pipeline guide reviews pipeline therapeutics for
Barth Syndrome (Other Diseases) by companies and universities/research
institutes based on information derived from company and industry-specific
sources. The pipeline guide covers pipeline products based on several stages of
development ranging from pre-registration till discovery and undisclosed
stages. The pipeline guide features descriptive drug profiles for the pipeline
products which comprise, product description, descriptive licensing and
collaboration details, R&D brief, MoA & other developmental activities.
The pipeline guide reviews key companies involved in Barth Syndrome (Other
Diseases) therapeutics and enlists all their major and minor projects.
The
pipeline guide evaluates Barth Syndrome (Other Diseases) therapeutics based on
mechanism of action (MoA), drug target, route of administration (RoA) and
molecule type. The pipeline guide encapsulates all the dormant and discontinued
pipeline projects. The pipeline guide reviews latest news related to pipeline
therapeutics for Barth Syndrome (Other Diseases)
To know more click on the link below:
Contact
Us:
Ken
Research
Ankur
Gupta, Head Marketing & Communications
+91
9015378249